A Novel B-cell Line (U-2932) Established from a Patient with Diffuse Large B-cell Lymphoma Following Hodgkin Lymphoma-Reference-Cited by-同舟云学术

A Novel B-cell Line (U-2932) Established from a Patient with Diffuse Large B-cell Lymphoma Following Hodgkin Lymphoma

Published:2002-01 Issue:11 Volume:43 Page:2179-2189
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Amini Rose-Marie,Berglund Mattias,Rosenquist Richard,von Heideman Anne,Lagercrantz Svetlana,Thunberg Ulf,Bergh Jonas,Sundström Christer,Glimelius Bengt,Enblad Gunilla

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/1042819021000032917

Reference40 articles.

1. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]

2. The interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas

3. Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: A clinico-pathological and immuno-histochemical population-based study of 32 patients

4. Identification of Common Germinal-Center B-Cell Precursors in Two Patients with Both Hodgkin's Disease and Non-Hodgkin's Lymphoma

5. Common Germinal-Center B-Cell Origin of the Malignant Cells in Two Composite Lymphomas, Involving Classical Hodgkin’s Disease and Either Follicular Lymphoma or B-CLL

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of New Diffuse Large B Cell Lymphoma Mouse Models;Cancers;2024-08-29

2. Epstein-Barr virus–encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma;Blood;2024-02-01

3. Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma;Molecular Cancer Therapeutics;2024-01-19

4. Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton’s tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics;PLOS ONE;2023-03-10

5. Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies;Leukemia;2023-02-15